About Aadi Bioscience
Aadi Bioscience Inc. (Aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. Aadi’s lead asset, FYARROTM (sirolimus albumin-bound nanoparticles for injectable suspension), is an mTOR inhibitor targeting cancers driven by genetic alterations in mTOR pathway genes. Supported by leading healthcare investors, Aadi is currently preparing for launch of FYARRO in advanced malignant PEComa, a rare type of sarcoma with no previously approved therapies.
Aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. A science-first mindset and entrepreneurial spirit is in our genes. Aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor TSC1/2 alterations) and novel combination trials.
Our culture emphasizes a deep passion for scientific innovation, collaboration, and commitment to improving patient outcomes in rare cancers. We are looking to hire proven functional leaders who can thrive in a fast-paced, rapidly evolving environment, and who aren’t afraid to roll up their sleeves to get things moving. Resourcefulness, comfort with ambiguity, a strong sense of ownership and a humble attitude are critical attributes for potential candidates.
Aadi Bioscience is proud to be an Equal Employment Opportunity employer committed to a diverse and dynamic workplace. We do not discriminate based upon race, religion, color, national origin, gender (including pregnancy, childbirth, or related medical conditions), sexual orientation, gender identity, gender expression, age, status as a protected veteran, status as an individual with a disability, or other applicable legally protected characteristics.